Two Sigma Investments LP Raises Stock Position in Capricor Therapeutics Inc (NASDAQ:CAPR)

Two Sigma Investments LP lifted its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR - Free Report) by 223.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 119,047 shares of the biotechnology company's stock after buying an additional 82,254 shares during the quarter. Two Sigma Investments LP owned approximately 0.26% of Capricor Therapeutics worth $1,643,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Summit Investment Advisors Inc. boosted its stake in Capricor Therapeutics by 54.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 1,345 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock valued at $64,000 after purchasing an additional 2,947 shares during the last quarter. Virtus ETF Advisers LLC bought a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $68,000. AlphaQuest LLC purchased a new stake in shares of Capricor Therapeutics in the 4th quarter worth approximately $78,000. Finally, New York State Common Retirement Fund increased its position in Capricor Therapeutics by 625.0% during the 4th quarter. New York State Common Retirement Fund now owns 5,800 shares of the biotechnology company's stock valued at $80,000 after buying an additional 5,000 shares in the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Trading Up 8.0%

CAPR traded up $1.05 during trading on Friday, hitting $14.23. 2,495,546 shares of the company's stock traded hands, compared to its average volume of 1,780,198. The stock has a market capitalization of $649.98 million, a price-to-earnings ratio of -13.42 and a beta of 0.84. The company's 50 day simple moving average is $10.32 and its two-hundred day simple moving average is $12.96. Capricor Therapeutics Inc has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The business had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. During the same period last year, the business earned ($0.31) earnings per share. On average, equities analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have commented on CAPR shares. Wall Street Zen downgraded Capricor Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Roth Capital began coverage on Capricor Therapeutics in a research report on Tuesday, May 20th. They issued a "buy" rating and a $31.00 price target for the company. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, May 14th. Finally, HC Wainwright restated a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research note on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to MarketBeat, Capricor Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $35.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.